Hemalkumar B Mehta
Overview
Explore the profile of Hemalkumar B Mehta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
985
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Heyward J, Segal J, Mehta H, Murray J
Pharmacoepidemiol Drug Saf
. 2025 Feb;
34(2):e70100.
PMID: 39961795
Background: The use of real-world data is increasing to examine immune-related adverse event (irAE) incidence and risk factors in immune checkpoint inhibitor (ICI) users. We aimed to validate five case...
2.
Bhatia A, Preiss A, Xiao X, Brannock M, Alexander G, Chew R, et al.
PLoS Med
. 2025 Jan;
22(1):e1004493.
PMID: 39823513
Background: Nirmatrelvir with ritonavir (Paxlovid) is indicated for patients with Coronavirus Disease 2019 (COVID-19) who are at risk for progression to severe disease due to the presence of one or...
3.
Mehta H, Sekhon V, Reeve E, Sheehan O, Boyd C, Green A
J Am Geriatr Soc
. 2024 Dec;
PMID: 39655514
No abstract available.
4.
Patanwala A, Flannery A, Mehta H, Hills T, McArthur C, Erstad B
Chest
. 2024 Oct;
PMID: 39426720
Background: Albumin infusions may be renally protective or harmful in patients with septic shock who have kidney impairment. This can affect the need for renal replacement therapy (RRT) and in-hospital...
5.
Alexander G, Garibaldi B, An H, Andersen K, Robinson M, Wang K, et al.
Med Care
. 2024 Oct;
63(1):9-17.
PMID: 39422569
Study Design: Retrospective cohort study. Objective: To characterize variation in dexamethasone and remdesivir use over time among hospitals. Background: Little is known about hospital-level variation in COVID-19 drug treatments in...
6.
Mehta H, Xiao X, An H, Alexander G
J Am Med Dir Assoc
. 2024 Oct;
25(12):105294.
PMID: 39370117
Objective: Residents of nursing homes are usually excluded from clinical trials, including trials to assess treatments for common conditions such as nonvalvular atrial fibrillation (NVAF). We aimed to quantify the...
7.
Patanwala A, Xiao X, Hills T, Higgins A, McArthur C, Alexander G, et al.
Crit Care Med
. 2024 Oct;
53(1):e29-e41.
PMID: 39365115
Objectives: COVID-19 treatment guidelines recommend baricitinib or tocilizumab for the management of hospitalized patients with COVID-19. We compared the effectiveness of baricitinib vs. tocilizumab on mortality and clinical outcomes among...
8.
Mehta H, Alexander G
JAMA Netw Open
. 2024 Sep;
7(9):e2432649.
PMID: 39240569
No abstract available.
9.
Xiao X, Alexander G, Mehta H
Pharmacoepidemiol Drug Saf
. 2024 Aug;
33(8):e5869.
PMID: 39099263
Purpose: Paxlovid is effective in reducing COVID-19 hospitalization and mortality. This study characterized Paxlovid use and evaluated racial/ethnic disparities over time among community-dwelling adults at high risk of progression to...
10.
Zhang S, Chou L, Swartz M, Mehta H, Goodwin J, Kuo Y, et al.
Front Oncol
. 2024 Apr;
14:1283252.
PMID: 38559557
Background: Older cancer survivors likely experience physical function limitations due to cancer and its treatments, leading to disability and early mortality. Existing studies have focused on factors associated with surgical...